Report library

AGS-003

AGS-003 (Argos Therapeutics/Kyowa Hakko Kirin) is a cancer vaccine in development for the first-line treatment of metastatic renal cell cancer (RCC) in combination with Sutent (sunitinib; Pfizer).

February 5, 2016

Alecensa

lecensa is a second-generation ALK inhibitor developed by Roche and Chugai. In some NSCLC

patients, abnormal ALK configuration leads to the production of proteins that promote and maintain

the malignant behavior of cancer cells (Soda et al., 2008).

August 30, 2018

Alimta

Alimta is an antifolate antineoplastic agent that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication.

August 30, 2018

Aliqopa

Aliqopa (copanlisib; Bayer) is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor with high selectivity for the p110-alpha/delta catalytic subunits. The PI3K pathway is crucial for normal B-cell development, and is subverted by follicular lymphoma (FL) to promote survival and growth.

January 31, 2019

ALKS 3831

ALKS 3831 is an orally available, fixed-dose combination of samidorphan (ALKS 33) and olanzapine being developed by Alkermes.

April 9, 2018

ALKS 5461

ALKS 5461 (Alkermes) is a fixed-dose combination of buprenorphine, a mu opioid receptor partial agonist and kappa opioid receptor antagonist, and samidorphan (ALKS 33), which is a proprietary opioid modulator.

March 29, 2019

ALKS 8700

ALKS 8700 is an oral monomethyl fumarate molecule being developed for the treatment of relapsing multiple sclerosis.

November 24, 2017

Allergan

$3,000.00

PharmaVitae explores Allergan’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.

October 10, 2018

Alofisel

Alofisel (darvadstrocel; TiGenix/Takeda) is a suspension of allogeneic expanded adipose-derived stem cells via intralesional injection.

August 2, 2018

Alpelisib

Alpelisib is a p110-alpha isoform-specific PI3K inhibitor. PI3K signaling plays a fundamental role in tumorigenesis, governing cell proliferation, survival, and motility, as well as angiogenesis.

February 5, 2016

Alprolix

Biogen and Swedish Orphan Biovitrum co-developed Alprolix (recombinant factor IX [rfIX] Fc fusion protein) for the treatment of hemophilia B. The therapy is a recombinant protein consisting of a single fIX fused with the dimeric Fc region of immunoglobulin G-1.

May 4, 2018

Alunbrig

Alunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.

September 8, 2018

Alzheimer’s Disease KOL Interview – UK

This interview with a UK key opinion leader (KOL) provides an overview of cost-effectiveness criteria that may be required to bring Alzheimer’s disease products successfully to the clinic in the UK. We also discuss current and potential treatment options, as well as unmet needs in Alzheimer’s disease.

January 20, 2019

Alzheimer’s Disease KOL Interview – US, Northeast

This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.

January 28, 2019

Alzheimer’s Disease KOL Interview – US, South

This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.

January 28, 2019

Alzheimer’s Disease Market and Forecast Analysis 2034

Alzheimer’s disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affects memory, cognition, and function.

February 25, 2019

Alzheimer’s KOL Interview

$399.00

KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.

October 21, 2015

Ampyra

Ampyra is a potassium channel blocker, marketed by Acorda Therapeutics and Biogen, which is

approved to improve walking ability in multiple sclerosis patients. Although Ampyra’s active molecule

fampridine (4-aminopyridine) is readily available, by using Elan’s Intestinal Protective Drug Absorption

System, Acorda has developed a sustained-released oral tablet formulation allowing twice-daily

dosing.

January 26, 2016

AMT-061

AMT-061 is being developed by uniQure as a gene therapy for hemophilia B patients. The product uses an adeno-associated virus as a vector to deliver the highly active Padua factor IX (fIX) variant, which has eightfold to ninefold greater activity than normal, wild-type fIX.

May 4, 2018

An Evolution in Partnering: Can CROs Lead the Way in Innovation?

$5,000.00

The concept of a drug development partnership between CRO and sponsor is the latest strategic evolution in the search for efficiency and innovation in the biopharmaceutical world.

November 3, 2016

Anemia in Chronic Kidney Disease KOL Interview – US, East Coast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for anemia in chronic kidney disease (CKD). Key topics discussed include current treatments for anemia in CKD, with a focus on ESAs and IV iron, and the future of HIF stabilizers as a potential treatment for the disease.

Anemia in Chronic Kidney Disease KOL Interview – US, West Coast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for anemia in chronic kidney disease (CKD). Key topics discussed include current treatments for anemia in CKD, with a focus on ESAs and IV iron, and the future of HIF stabilizers as a potential treatment for the disease.

Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Midwest

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning anemia in chronic kidney disease, with a focus on the anticipated reimbursement of HIF stabilizers in the US.

Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Southwest

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning anemia in chronic kidney disease, with a focus on the anticipated reimbursement of HIF stabilizers in the US.

Angiomax

Angiomax is a direct thrombin inhibitor which prevents the formation of fibrin from fibrinogen and the activation of coagulation factor XII.

April 14, 2016

Angioplasty Catheters Market

$4,750.00

This comprehensive medical market and technology report provides an overview and in-depth market analysis of angioplasty catheters, specifically plain old balloon angioplasty (POBA), drug-coated balloon (DCB), cutting balloon, and scoring balloon catheters, used in the treatment of severe coronary artery disease (CAD) and peripheral artery disease (PAD).

November 28, 2017

Anoro

GlaxoSmithKline and Theravance (now Innoviva) developed the once-daily inhaled combination, Anoro, consisting of umeclidinium and vilanterol for the treatment of chronic obstructive pulmonary disease (COPD).

July 31, 2018

Apalutamide

Apalutamide (Johnson & Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently inhibits its nuclear import, as well as its ability to bind to DNA. Apalutamide has a similar mechanism of action to Xtandi (enzalutamide; Pfizer/Astellas).

January 18, 2018